SpringWorks Therapeutics, Inc.

SWTXNASDAQHealthcare

$46.99

+$0.01(+0.02%)

Market Cap$3.5B

P/E Ratio—

52W High$62

52W Low$28.21

Avg Volume5.6M

Open$46.99

Beta0.70

Free Cash Flow Financials Revenue

SpringWorks Therapeutics, Inc. (SWTX) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

SWTX · free cash flow · updated Jun 9, 2026

Core FCF metrics

SWTX · FCF · TTM · margin & CAGR

Free cash flow was −$180.1M for FY2024 (fiscal year ending 2024-12-31), up 21.8% year-over-year The FCF margin was -94.0%.

FY2024 Free Cash Flow−$180.1M▲ +21.8% YoY

Trailing 12M (TTM)−$174.3Mtrailing 4 quarters sum

FCF Margin-94.0%−$180.1M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

SWTX · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2024Latest−$175.6M(4M)−$180.1M▲ +21.8%-94.0%

FY2023−$222.8M(7M)−$230.2M▼ 34.0%—

FY2022−$161.6M(10M)−$171.8M▼ 32.2%—

FY2021−$127.9M(2M)−$129.9M▼ 295.6%—

FY2020−$32.2M(1M)−$32.8M▲ +31.8%-93.8%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

SWTX · P/FCF · FCF yield · FCF per share

SpringWorks Therapeutics, Inc. (SWTX) reported negative free cash flow of −$0.18B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2024 · 2024-12-31

Cash flow statement summary

SWTX · cash flow statement · operating / investing / financing

For FY2024, SpringWorks Therapeutics, Inc. generated −$175.6M in operating cash flow and spent 4M in capital expenditures, yielding −$180.1M in free cash flow.

Operating Activities

−$175.6M

Cash from core business operations

2024-12-31

Investing Activities

+$64.5M

CapEx, acquisitions & investments

2024-12-31

Financing Activities

+$4.8M

Buybacks, dividends & debt

2024-12-31

FCF FormulaOperating CF (−$175.6M) − |CapEx| (4M) = FCF (−$180.1M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

SWTX vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

SpringWorks Therapeutics, Inc.YOU

SWTX

−$180.1M+21.8%-94.0%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

SpringWorks Therapeutics, Inc. (SWTX) reported free cash flow of −$180.1M for FY2024 (fiscal year ending 2024-12-31), up 21.8% year-over-year. The FCF margin was -94.0%.

SpringWorks Therapeutics, Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 8 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

SWTX free cash flow · 8 questions

SpringWorks Therapeutics, Inc. free cash flow was −$180.1M for FY2024, up 21.8% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$174.3M.

SWTX free cash flowSWTX FCFSWTX FCF 2024SWTX free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · SpringWorks Therapeutics, Inc. · SpringWorks Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026